DNTH · NASDAQ · STOCK
Dianthus Therapeutics (DNTH) Stock Analysis
$82.36
52W $32.22 – $117.88
49/100
$4.61B
-633.6
0.08
Is DNTH Bullish or Bearish?
Mixed.
Innellis AI committee rates Dianthus Therapeutics, Inc. (DNTH) Watch with a composite score of 49/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +10.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -9.17 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — revenue declining -60.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -22.5% -- cheap may mean cheap for a reason — Value
- Revenue declining -60.8% YoY -- this is not a growth story right now — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 12 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 32.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
49/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 96%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -22.5% -- cheap may mean cheap for a reason
Growth Analyst
bearish
25
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -60.8% YoY -- this is not a growth story right now
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 12 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 32.7% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 49.2 to 49.2.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
12.3
Oversold
MACD Histogram
-0.593
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$69.56
Resistance
$95.99
Bollinger %B
0.17
Inside Bands
Price vs Moving Averages
EMA 9
$86.18
Below
EMA 21
$91.59
Below
EMA 50
$96.93
Below
EMA 200
$82.99
Below
Fundamental Analysis
Valuation
54
Growth
33
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-633.6×
P/B Ratio
3.94×
PEG Ratio
—
Dividend Yield
0.00%
52W High
$117.88
52W Low
$32.22
Quality & Growth
ROE
-3290.2%
ROA
-3057.6%
Gross Margin
9600.8%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -633.6 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 104.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -32.9%; Return on assets of -30.6%; Net margin of -1570.9%; Gross margin of 96.0%; Current ratio of 26.10 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.78); Most recent quarter missed estimates by 2.9%; EPS growth decelerating (+40.6% -> -5.9% QoQ); Analyst estimates rising over recent quarters
Get the Full DNTH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →